SCHEMBL17015697

SCHEMBL17015697

O=C(c1cccc(-n2c3ccccc3c3ccc4c(ccn4-c4ccc(-c5ccccc5)cc4)c32)c1)c1ccc2ccccc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
MAPK1 P28482 2/20 0.35
CNR2 P34972 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
CNR1 P21554 1/20 0.35
THPO P40225 1/20 0.35
MTOR P42345 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015230 0.95 CLK1 (0.40) CLK1DYRK1ADYRK1BMAPK1CNR2
SCHEMBL17015698 0.94 MAPK1 (0.36) MAPK1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL17015779 0.94 CLK1 (0.36) CLK1DYRK1ADYRK1BMAPK1CNR2
SCHEMBL17015695 0.92 CYP19A1 (0.38) CNR2CYP1A2CYP3A4CYP2C19CNR1
SCHEMBL17016183 0.91 CNR2 (0.38) CLK1DYRK1ADYRK1BMAPK1CNR2
SCHEMBL17015226 0.91 CNR2 (0.38) CLK1DYRK1ADYRK1BMAPK1CNR2
SCHEMBL17016175 0.91 ROCK2 (0.40) CLK1DYRK1ADYRK1BMAPK1CNR2
SCHEMBL17015774 0.89 CNR2 (0.35) MAPK1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL17015691 0.87 CA12 (0.38) CNR2CYP1A2CYP3A4CYP2C19LMNA
SCHEMBL17015225 0.87 CNR2 (0.40) MAPK1CNR2CYP3A4LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 CLK1 3234/4885DYRK1A 4035/4885DYRK1B 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.